Skip to content

Comorbidities and overlap

TL;DR — Fibromyalgia rarely travels alone. The chronic overlapping pain conditions (COPC) framework treats FM, IBS, TMD, headache, interstitial cystitis/bladder pain, endometriosis-associated pain, and ME/CFS as co-prevalent expressions of shared (largely central) vulnerability — a view now backed by twin studies (comorbidity partly explained by familial factors) and by FM's genetic correlations >0.7 with low back pain, PTSD, and IBS. Quantified overlap is large: lifetime IBS in ~77% of FM patients, TMD in ~77%, and ~70% of chronic-fatigue patients meeting FM tender-point criteria; the FM-vs-ME/CFS boundary remains a genuinely unresolved classification problem. Psychiatric comorbidity is substantial but often overstated by screening scales: structured interviews give current MDD ~25% and lifetime ~65%; roughly a third have current or lifetime PTSD, panic disorder, or bipolar disorder. Concomitant FM occurs in ~21% of RA, ~13% of ankylosing spondylitis, ~18% of PsA, and ~25% of SLE, and inflates patient-reported disease-activity components (DAS28 ≈ +1.24 in RA; BASDAI ≈ +2.2 in AS) — a practically important trap for treat-to-target decisions. Whether comorbidity clusters define true FM subtypes is suggested (3-cluster and 5-class solutions) but unproven.

The COPC framework

Maixner and colleagues formalized "chronic overlapping pain conditions": common chronic pain disorders that co-occur far above chance, share biopsychosocial risk architecture, and are so entangled that trial populations recruited for one "pure" condition misrepresent the mixed patients seen in practice (Maixner 2016, PMID 27586833). Supporting evidence layers:

  • Twin evidence: in 44,897 Swedish twins, CWP co-occurred with chronic fatigue (OR 23.5, 95% CI 19.7–28.2), joint pain (OR 7.4), depressive symptoms (OR 5.3), and IBS (OR 5.2); in co-twin control analyses the psychiatric associations disappeared and most somatic ones attenuated but persisted — i.e., comorbidity is partly mediated by shared familial (genetic + family-environment) factors, to a degree that is disorder-specific (Kato 2006, PMID 16908799). Multivariate modeling (best fit in the women's data) identified a latent functional-somatic liability distinct from the psychiatric one (Kato 2009, PMID 18578896).
  • Genetic evidence: the 2.5-million-person FM GWAS found genetic correlations above 0.7 with low back pain, PTSD, and IBS and broad positive correlations across chronic pain, psychiatric, and somatic disorders (Kerrebijn 2026, PMID 42521817); genomic SEM fits a single shared factor across FM, insomnia, depression, and anxiety (rg 0.55–0.84) (Lin 2026, PMID 41576141). See genetics-and-risk-factors.
  • Urological arm: systematic review of 1,037 articles found substantial overlap between IC/PBS, chronic pelvic pain, and the non-urological conditions (FM, CFS, TMD, IBS), with up to 79% IBS-symptom comorbidity in chronic pelvic pain, though case definitions were inconsistent (Bullones Rodríguez 2013, PMID 23234637).

Quantified overlap with individual conditions

Condition Best available numbers Source (design, criteria)
ME/CFS 70% of primary-care chronic-fatigue patients had diffuse pain + tender-point exams similar to FM patients'; most CFS-criteria patients also met FM criteria Goldenberg 1990 (PMID 2317224; n=27 CF, tender-point exam)
IBS Lifetime IBS 77% in FM vs 18% controls; 92% in CFS; CWP-IBS OR 5.2 population-wide; ACTTION review range 39–76% for chronic-pain comorbidities incl. IBS Aaron 2000 (PMID 10647761; clinic samples); Kato 2006 (PMID 16908799; twins); Kleykamp 2021 (PMID 33383293; systematic review, 31 studies)
TMD TMD in FM: pooled 76.8% (95% CI 69.5–83.3), mostly myogenous (63.1%); FM in TMD: pooled 32.7% (4.5–71.0); CWP in TMD 30–76% Yakkaphan 2023 meta-analysis, 19 studies (PMID 37975782; criteria vary across studies)
Migraine / tension headache FM in 6.0% (95% CI 5.1–6.8) of 2,782 Chinese hospital patients with primary headache (modified ACR 2010); higher in chronic migraine (11.1%) and chronic TTH (11.5%) than episodic forms; non-Chinese clinic studies cited at ~one-third; headache-CWP association did not attenuate in co-twin analysis (familial confounding minimal) Dong 2023 (PMID 36651491); Kato 2006 (PMID 16908799)
Interstitial cystitis / bladder pain FM among the conditions significantly over-represented in 2,405 IC patients (with allergies, IBS, sensitive skin); IC also linked to 100× IBD and 30× SLE vs general population (survey methodology, crude comparisons) Alagiri 1997 (PMID 9146002)
Endometriosis FM 5.9% vs 3.4% in general US female population; CFS 4.6% vs 0.03%; plus elevated autoimmune and atopic disease — Endometriosis Association survey of 3,680 members (surgically diagnosed endometriosis; self-report, advocacy-sample bias) Sinaii 2002 (PMID 12351553)
Chronic fatigue (symptom) OR 23.5 for chronic fatigue in CWP, the largest single comorbidity signal in the twin registry Kato 2006 (PMID 16908799)

Methodological caution: clinic-based samples (Aaron, Mohammad, Yakkaphan inputs) inflate overlap relative to population samples (Kato, Dong) — Berkson's bias; the population-level ORs (5–24) are the defensible core claim.

The FM-vs-ME/CFS boundary problem

Both syndromes combine fatigue, pain, unrefreshing sleep, and cognitive difficulty; assignment often reflects the presenting complaint and the specialty consulted. Evidence on both sides:

  • For a shared spectrum: massive symptom overlap and co-diagnosis (Goldenberg 1990, PMID 2317224; Aaron 2000, PMID 10647761); a stereotyped post-infective syndrome that can evolve toward either label, predicted by acute-illness severity not psychology (Hickie 2006, PMID 16950834); shared latent liability in twins (Kato 2009, PMID 18578896).
  • For distinct entities: reviews cataloguing direct comparisons document FM-vs-CFS differences across physiological and biomarker parameters, arguing the "single syndrome" hypothesis is empirically testable and, on the evidence they assemble, disfavored (Abbi & Natelson 2013, PMID 22927538; Natelson 2019, PMID 30795933).
  • Unresolved: no biomarker adjudicates the boundary; the two case-definition traditions (pain-anchored FM criteria vs ME/CFS criteria anchored on fatigue with required post-exertional malaise in the current IOM 2015 definition — Clayton 2015, PMID 25668027) partition one comorbid population differently. This is raw material for OPEN-QUESTIONS.

Psychiatric comorbidity — with numbers

  • Major depressive disorder: pooled point prevalence 25% (95% CI 19–31%) and lifetime 65% (59–71%) by structured clinical interview (11 studies); self-administered screening scales give ~45% point prevalence — i.e., scales nearly double the apparent burden (Løge-Hagen 2019, PMID 30699852).
  • ACTTION systematic review (31 clinical-epidemiology studies): lifetime depression/MDD weighted prevalence up to 63%; roughly one-third of FM patients with current or lifetime bipolar disorder, panic disorder, or PTSD; generalized anxiety, OCD, and phobias much less common; chronic-pain comorbidities (headache, IBS, myofascial pain, TMD) 39–76%; no incidence data existed in any reviewed study (Kleykamp 2021, PMID 33383293).
  • PTSD/trauma: meta-analysis of 71 controlled studies across functional somatic syndromes: trauma exposure OR 2.7 (95% CI 2.27–3.10); the PTSD association exceeded that of abuse subtypes (Afari 2014, PMID 24336429). FM's genetic correlation with PTSD >0.7 (Kerrebijn 2026, PMID 42521817) suggests part of this is shared inherited liability rather than simple causation.
  • Familial coaggregation: FM and major mood disorder coaggregate in families (OR 1.8, 95% CI 1.1–2.9) (Arnold 2004, PMID 15022338) — depression comorbidity is partly familial, not purely reactive; conversely, co-twin analyses showed CWP-psychiatric associations were largely explained by familial confounding (Kato 2006, PMID 16908799).

Concomitant FM in inflammatory rheumatic disease — the practical literature

Systematic review and meta-analysis of 40 studies (Duffield 2018, PMID 29788461):

Underlying disease Concomitant FM prevalence Effect on disease-activity scores
Rheumatoid arthritis 21% pooled (range 4.9–52.4%) DAS28 higher by 1.24 (95% CI 1.10–1.37) when FM present
Axial SpA (AS) 13% pooled in AS (range 4.1–25.2% across axSpA) BASDAI higher by 2.22 (95% CI 1.86–2.58)
Psoriatic arthritis 18% pooled (range 9.6–27.2%) Higher disease-activity scores in available studies
SLE 25.3% (22/87, Yunus criteria, single cross-sectional cohort) Objective activity (SLAM) no different with FM, but physician and patient VAS decorrelated from SLAM in FM patients (Morand 1994, PMID 7951304)

Why it matters clinically: the FM-inflated components are the subjective ones (tender joint count, patient VAS) (Duffield 2018, PMID 29788461). Concomitant FM therefore mimics refractory inflammatory disease, risking unnecessary biologic escalation in RA/axSpA and misread flares in SLE — an argument for FM screening before treat-to-target escalation. Composite scores that lean on patient-reported components are systematically biased upward in the ~1-in-5 patients with concomitant FM.

  • Post-COVID overlap: the same boundary issues now play out in long COVID, where 31–40% of post-acute cohorts meet FM criteria (Ciaffi 2023, PMID 37296705) and definitional inconsistency is the rule (Plaut 2026, PMID 42174645); see genetics-and-risk-factors for the trigger-level evidence.

Do comorbidity clusters define subtypes?

  • Within-FM clustering on tenderness + mood + cognition (n=97, ACR 1990): three clusters — (1) moderate mood scores with low tenderness (n=50), (2) high distress/high catastrophizing/high tenderness (n=31), (3) extreme tenderness with normal mood ("neurobiological" subtype, n=16) (Giesecke 2003, PMID 14558098). Small sample; replication at scale pending.
  • Population level (28,531 twins, 9 functional somatic symptoms): latent class analysis gave five classes — unaffected, fatigue-dominant, GI-dominant, pain-dominant, and a multi-symptom class; class membership showed only modest genetic influence (7–29%), majority unique-environment (Kato 2010, PMID 20403503). Suggests single-syndrome vs multi-syndrome ("complicated") presentations may matter more than which syndrome label is applied.
  • Genetic subtyping is beginning: shared-factor models (Lin 2026, PMID 41576141) and cross-trait correlations (Kerrebijn 2026, PMID 42521817) support a general liability plus condition-specific components — consistent with Kato's two-latent-trait twin result (PMID 18578896) — but no genetic or clinical cluster has yet been shown to predict treatment response.

Verdict: clusters exist and replicate in outline (a low-distress/high-tenderness group, a high-distress group, a multi-syndrome group), but "subtype" status would require stability over time and differential prognosis/treatment response, which remain undemonstrated.

Open questions

  • Can any biomarker or quantitative trait place an individual patient on the FM-ME/CFS boundary better than symptom-anchored criteria do? The comparative-difference literature (PMIDs: 22927538, 30795933) has not produced a validated discriminator.
  • Which COPC pairs share causal biology vs merely correlated liability? Co-twin attenuation differs by condition (headache barely attenuates, psychiatric associations vanish; Kato 2006, PMID 16908799) — condition-by-condition Mendelian randomization using the new FM GWAS (PMID 42521817) is now feasible and largely undone.
  • Does screening for and treating concomitant FM in RA/axSpA prevent inappropriate biologic escalation and improve outcomes? The score-inflation effect is quantified (PMID 29788461) but no strategy trial exists.
  • Are Giesecke-type clusters (PMID 14558098) stable longitudinally, and do they predict differential response to centrally acting vs peripherally acting therapy?
  • Why is prevalence of FM in primary headache roughly five-fold lower in a Chinese hospital series (6%; PMID 36651491) than in the non-Chinese clinic reports (~one-third) cited therein — criteria, ascertainment, or true population difference?
  • Psychiatric comorbidity numbers rest on cross-sectional prevalence; no reviewed study reported incidence or temporal ordering relative to FM onset (Kleykamp 2021, PMID 33383293). Which comes first, and for whom?

References

  1. Maixner W, et al. Overlapping chronic pain conditions: implications for diagnosis and classification. J Pain. 2016;17(9 Suppl):T93-T107. PMID 27586833
  2. Kato K, et al. Chronic widespread pain and its comorbidities: a population-based study. Arch Intern Med. 2006;166(15):1649-54. PMID 16908799
  3. Kato K, et al. A population-based twin study of functional somatic syndromes. Psychol Med. 2009;39(3):497-505. PMID 18578896
  4. Kato K, et al. Latent class analysis of functional somatic symptoms in a population-based sample of twins. J Psychosom Res. 2010;68(5):447-53. PMID 20403503
  5. Kerrebijn I, et al. The genetic architecture of fibromyalgia across 2.5 million individuals. Nat Med. 2026;32(8):3060-3070. PMID 42521817
  6. Lin L, et al. Shared latent genetic liability across fibromyalgia and psychiatric traits. PLoS Genet. 2026;22(1):e1012034. PMID 41576141
  7. Bullones Rodríguez MÁ, Afari N, Buchwald DS. Evidence for overlap between urological and nonurological unexplained clinical conditions. J Urol. 2013;189(1 Suppl):S66-74. PMID 23234637
  8. Goldenberg DL, et al. High frequency of fibromyalgia in patients with chronic fatigue seen in a primary care practice. Arthritis Rheum. 1990;33(3):381-7. PMID 2317224
  9. Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med. 2000;160(2):221-7. PMID 10647761
  10. Kleykamp BA, et al. The prevalence of psychiatric and chronic pain comorbidities in fibromyalgia: an ACTTION systematic review. Semin Arthritis Rheum. 2021;51(1):166-174. PMID 33383293
  11. Yakkaphan P, et al. Temporomandibular disorders and fibromyalgia prevalence: a systematic review and meta-analysis. J Oral Facial Pain Headache. 2023;37(3):177-193. PMID 37975782
  12. Dong Z, et al. The prevalence and clinical features of fibromyalgia in Chinese hospital patients with primary headache. Headache. 2023;63(1):62-70. PMID 36651491
  13. Alagiri M, et al. Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes. Urology. 1997;49(5A Suppl):52-7. PMID 9146002
  14. Sinaii N, et al. High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. Hum Reprod. 2002;17(10):2715-24. PMID 12351553
  15. Abbi B, Natelson BH. Is chronic fatigue syndrome the same illness as fibromyalgia: evaluating the 'single syndrome' hypothesis. QJM. 2013;106(1):3-9. PMID 22927538
  16. Natelson BH. Myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia: definitions, similarities, and differences. Clin Ther. 2019;41(4):612-618. PMID 30795933
  17. Hickie I, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;333(7568):575. PMID 16950834
  18. Løge-Hagen JS, et al. Prevalence of depressive disorder among patients with fibromyalgia: systematic review and meta-analysis. J Affect Disord. 2019;245:1098-1105. PMID 30699852
  19. Afari N, et al. Psychological trauma and functional somatic syndromes: a systematic review and meta-analysis. Psychosom Med. 2014;76(1):2-11. PMID 24336429
  20. Arnold LM, et al. Family study of fibromyalgia. Arthritis Rheum. 2004;50(3):944-52. PMID 15022338
  21. Duffield SJ, et al. Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2018;57(8):1453-1460. PMID 29788461
  22. Morand EF, et al. Fibromyalgia syndrome and disease activity in systemic lupus erythematosus. Lupus. 1994;3(3):187-91. PMID 7951304
  23. Ciaffi J, et al. Post-acute COVID-19 joint pain and new onset of rheumatic musculoskeletal diseases: a systematic review. Diagnostics (Basel). 2023;13(11):1850. PMID 37296705
  24. Plaut S. A systematic scoping review and conceptual analysis of new-onset fibromyalgia manifestations after non-hospitalized COVID-19. J Transl Med. 2026;24(1). PMID 42174645
  25. Giesecke T, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum. 2003;48(10):2916-22. PMID 14558098
  26. Clayton EW. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: an IOM report on redefining an illness. JAMA. 2015;313(11):1101-2. PMID 25668027